Pharmaceutical compositions of sitagliptin
The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.
1. A stable pharmaceutical composition comprising sitagliptin base and at least one beneficial agent in an amount of about 1% to about 20% by weight of the composition, wherein the beneficial agent is a pH modifying agent which provides pH from about 3 to about 8 to the composition; wherein the pH modifying agent is selected from the group consisting of gluconic acid, lactic acid, glycolic acid, ascorbic acid, malic acid, tartaric acid, tartronic acid and mucic acid; and wherein the composition contains less than 0.2% by weight of 3-Trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride (impurity-I) wherein the composition is prepared by a process comprising the steps of:
(a) mixing the sitagliptin base and one or more pharmaceutically acceptable excipients; granulating the mixture with or without a binder solution to obtain sitagliptin granules and optionally coating the granules;
(b) mixing at least one beneficial agent and one or more pharmaceutically acceptable excipients; granulating the mixture with or without a binder solution to obtain granules and optionally coating the granules;
(c) blending the granules obtained in step (a) and (b) with one or more pharmaceutically acceptable excipients; and
(d) compressing the blended granules into a tablet.
2. The stable pharmaceutical composition according to claim 1 , wherein the sitagliptin is in an amorphous form.
3. The stable pharmaceutical composition according to claim 1 , wherein the sitagliptin is in a crystalline form.
4. The stable pharmaceutical composition according to claim 1 , wherein the sitagliptin has an average particle size diameter below 25 microns.
5. The stable pharmaceutical composition according to claim 1 , wherein the composition further comprises one or more pharmaceutically acceptable excipients comprising diluents, binders, disintegrants, glidants, lubricants, sweeteners/taste masking agents, compression aids, colorants, flavors or the combinations thereof.
6. The stable pharmaceutical composition according to claim 1 , wherein the composition is in the form of a solid dispersion.
7. The stable pharmaceutical composition according to claim 1 , wherein the beneficial agent is malic acid.